Incyte stock (US45337C1027): Patent win secures Jakafi protection

Incyte secured a consent judgment against Hikma on October 27, 2025, protecting ruxolitinib patents until expiration and blocking generic competition for its key drug Jakafi.

Incyte Corporation announced a significant legal victory in its patent infringement case against Hikma Pharmaceuticals. On October 27, 2025, the U.S. District Court in Delaware entered a consent judgment and permanent injunction, prohibiting Hikma from commercializing its generic version of Jakafi (ruxolitinib) until all five patents-in-suit expire, PatSnap as of October 2025. This development safeguards revenue from Incyte's blockbuster drug, approved for myelofibrosis and polycythemia vera.

Incyte stock traded at $98.56 USD on Nasdaq, up 0.81% on the day with bullish technical signals, Pluang as of May 2026. The ruling came without damages or admissions of infringement, as both parties stipulated to the judgment under Hatch-Waxman litigation rules.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Incyte Corporation
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Wilmington, Delaware, USA
• Core markets: Oncology, hematology
• Key revenue drivers: Jakafi (ruxolitinib)
• Home exchange/listing venue: Nasdaq (INCY)
• Trading currency: USD

Incyte: core business model

Incyte Corporation develops small-molecule drugs targeting oncology and inflammation. The company focuses on precision medicine for unmet needs in hematologic malignancies and solid tumors. Its lead product, Jakafi, generated substantial U.S. revenue as a JAK inhibitor for rare blood cancers, providing stable cash flow for its pipeline.

Main revenue and product drivers for Incyte

Jakafi remains Incyte's primary revenue driver, treating myelofibrosis and graft-versus-host disease. Ruxolitinib sales underpin the business, with the recent patent protection extending market exclusivity. Partnerships, such as with Prelude Therapeutics, added $4.6 million in collaboration revenue in Q1 2026, StockTitan as of May 2026. Pipeline candidates in dermatology and other areas diversify growth.

Industry trends and competitive position

The biopharma sector sees rising demand for targeted therapies in oncology. Incyte holds a strong position in JAK inhibitors, with Jakafi's patent win fending off generics. U.S. investors benefit from Nasdaq listing and exposure to the $100B+ oncology market.

Why Incyte matters for US investors

Listed on Nasdaq, Incyte offers U.S. retail investors direct access to innovative biopharma with heavy reliance on the domestic market. Jakafi's U.S. approvals and sales make it sensitive to FDA dynamics and healthcare spending trends.

Conclusion

The patent judgment against Hikma bolsters Incyte's Jakafi franchise amid competitive pressures in biotech. Recent collaboration revenue signals pipeline progress, while stock momentum reflects market approval. Investors track upcoming earnings and regulatory catalysts for sustained performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.